Ani Pharmaceuticals INC 8-K filings

ANI Pharmaceuticals announced record second quarter 2026 financial results, showcasing a 25.9% year-over-year increase in net revenues to $266.0 million and a 32.4% rise in adjusted EBITDA to $71.6 million, while reaffirming full-year guidance.

ANI Pharmaceuticals stockholders approved the Amended and Restated 2022 Stock Incentive Plan and ratified the appointment of Ernst & Young LLP as auditor at the company's 2026 Annual Meeting.

ANI Pharmaceuticals, Inc. has published an updated investor presentation, projecting approximately $1.1 billion in total net revenue for 2026, with its Rare Disease business expected to constitute about 60% of total revenues.

ANI Pharmaceuticals announced robust first-quarter 2026 financial results, exceeding expectations with a 20.5% year-over-year revenue increase and raising its full-year financial guidance.

ANI Pharmaceuticals, Inc. announced the dismissal of EisnerAmper LLP and the appointment of Ernst & Young LLP as its new independent registered public accounting firm.

ANI Pharmaceuticals forecasts significant revenue and profit growth for 2026, fueled by its expanding Rare Disease segment and strong performance from Cortrophin Gel.

ANI Pharmaceuticals announced record fourth quarter and full year 2025 financial results, driven by strong growth in its Rare Disease and Generics segments, and reaffirmed robust 2026 financial guidance.

ANI Pharmaceuticals, Inc. announced strong preliminary 2025 financial results and robust 2026 guidance, projecting over $1 billion in total net revenues, primarily fueled by its Rare Disease business.

ANI Pharmaceuticals announced a leadership transition on its Board of Directors, with Patrick D. Walsh stepping down as Chairman and Thomas J. Haughey elected as his successor.

ANI Pharmaceuticals, Inc. updated its investor presentation, raising full-year 2025 financial guidance for total revenue, Cortrophin Gel revenue, Adjusted EBITDA, and Adjusted Diluted EPS, driven by robust performance in its Rare Disease and Generics segments.

ANI Pharmaceuticals reported record third-quarter 2025 financial results, driven by strong Rare Disease and Generics performance, leading to an upward revision of its full-year 2025 guidance.

ANI Pharmaceuticals, Inc. has completed the mandatory conversion of all outstanding Series A Convertible Preferred Shares into common stock, eliminating preferred equity.

ANI Pharmaceuticals, Inc. updated its 2025 financial guidance upwards, driven by exceptional performance in its Rare Disease segment, particularly Cortrophin Gel, and robust generics growth.

ANI Pharmaceuticals reports record second quarter 2025 financial results, driven by strong Rare Disease and Generics performance, leading to increased full-year guidance.

A jury has ruled against ANI Pharmaceuticals, awarding no damages in its lawsuit against CG Oncology regarding a 5% royalty on cretostimogene sales.

ANI Pharmaceuticals announced mixed results from its NEW DAY Study for ILUVIEN in early diabetic macular edema, failing to meet its primary endpoint in the intent-to-treat population but showing benefits in a per-protocol analysis and extended re-treatment intervals.

ANI Pharmaceuticals announced preliminary Q2 2025 financial results and mixed outcomes from its NEW DAY clinical trial for ILUVIEN in diabetic macular edema, missing its primary endpoint but demonstrating a statistically significant reduction in time to first supplemental injection.

ANI Pharmaceuticals, Inc. presented at the Jefferies Global Healthcare Conference, reaffirming its robust growth trajectory driven by its Rare Disease and Generics segments and raising its full-year 2025 financial guidance for the second time.

ANI Pharmaceuticals' stockholders approved an increase in authorized common stock shares and amendments to the company's stock incentive and employee stock purchase plans at the 2025 Annual Meeting.

ANI Pharmaceuticals announces a revised full-year guidance for 2025, driven by strong Q1 results and continued growth in its rare disease and generics businesses.

ANI Pharmaceuticals announces record first quarter 2025 financial results, driven by strong performance in Rare Disease and Generics segments, and raises its full-year 2025 guidance.

ANI Pharmaceuticals supplements its proxy statement to clarify details regarding its Amended and Restated 2022 Stock Incentive Plan, specifically addressing non-shareholder approved inducement grants.

ANI Pharmaceuticals eliminates its royalty obligation on ILUVIEN and YUTIQ by purchasing the rights from SWK Funding LLC for $17.25 million.

ANI Pharmaceuticals announces FDA approval for an expanded label for ILUVIEN, now including treatment for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME).

ANI Pharmaceuticals projects significant revenue and EBITDA growth in 2025, fueled by its rare disease business and strategic acquisitions.

ANI Pharmaceuticals announced record fourth-quarter and full-year 2024 financial results, driven by strong performance in its Rare Disease and Generics businesses, and raised its 2025 financial guidance.

ANI Pharmaceuticals presented at the Guggenheim Biotech Conference, showcasing robust growth driven by its Rare Disease business and strategic acquisitions.

ANI Pharmaceuticals expects to meet or exceed its 2024 financial guidance and forecasts continued growth in 2025, driven by its Rare Disease franchise.

ANI Pharmaceuticals presented at the Jefferies Healthcare Conference, showcasing significant growth in its rare disease portfolio and continued strength in its generics business.

ANI Pharmaceuticals reported record third-quarter revenue and increased its full-year 2024 guidance, driven by strong performance in its Rare Disease and Generics segments and the acquisition of Alimera Sciences.